Dbv Technologies (DBVTF) 43.2700 $DBVTF
DBV Technologies: Spoon-Feeding Investors A Buying Opportunity
Don Dion - at Seeking Alpha - Thu Nov 20, 10:16AM CST
U.S. IPO Weekly Recap: With Just 3 IPOs, More Companies Postpone Than Go Public
Renaissance Capital IPO Research - at Seeking Alpha - Sun Oct 26, 12:22PM CDT
Three IPOs raised $164 million, bringing the year's total up to 231 offerings and $74 billion in proceeds. Six deals were expected to raise $550 million to make it the first week in over a month to raise under $1 billion. However, three of those...
ABCW: 33.49 (unch), PRTO: 10.45 (unch)
House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Fri Sep 26, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h2mn8/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies SA - Stallergenes S.A. - Circassia Holdings Ltd. - Anergis SA - Biomay AG Drug Profiles - Actair - allergenic pollen extract of timothy - MK-8237 - House Dust Mite-SPIRE - Subunit Vaccine for Mite Allergy - AllerDM - Viaskin House Dust Mite - PL-103 For more information visit http://www.researchandmarkets.com/research/2h..._dust_mite
Peanut Allergy Pipeline Review, H2 2014 - 9 Companes and 11 Drug Profiles
M2 - Thu Aug 07, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7hqg4k/peanut_allergy) has announced the addition of the "Peanut Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peanut Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peanut Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioTech Tools - DBV Technologies SA - HAL Allergy BV - Anergis SA - Immunomic Therapeutics, Inc. - Tunitas Therapeutics, Inc. - Perosphere Inc. - Sementis Ltd - Allergen Research Corporation Drug Profiles - DBV-712 - Allergen for Peanut Allergy - HALMPE-1 - ARA-LAMP-Vax - Recombinant Protein for Peanut Allergy - pnut-ASIT - DN-1017 - Vaccine for Peanut Allergy - Recombinant Vector Vaccine for Peanut Allergy - Vaccine for Peanut Allergy - PER-1080 For more information visit http://www.researchandmarkets.com/research/7h...ut_allergy
DBV Technologies: Spoon-Feeding Investors A Buying Opportunity
Don Dion - at Seeking Alpha - Thu Nov 20, 10:16AM CST
U.S. IPO Weekly Recap: With Just 3 IPOs, More Companies Postpone Than Go Public
Renaissance Capital IPO Research - at Seeking Alpha - Sun Oct 26, 12:22PM CDT
Three IPOs raised $164 million, bringing the year's total up to 231 offerings and $74 billion in proceeds. Six deals were expected to raise $550 million to make it the first week in over a month to raise under $1 billion. However, three of those...
ABCW: 33.49 (unch), PRTO: 10.45 (unch)
House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Fri Sep 26, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h2mn8/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies SA - Stallergenes S.A. - Circassia Holdings Ltd. - Anergis SA - Biomay AG Drug Profiles - Actair - allergenic pollen extract of timothy - MK-8237 - House Dust Mite-SPIRE - Subunit Vaccine for Mite Allergy - AllerDM - Viaskin House Dust Mite - PL-103 For more information visit http://www.researchandmarkets.com/research/2h..._dust_mite
Peanut Allergy Pipeline Review, H2 2014 - 9 Companes and 11 Drug Profiles
M2 - Thu Aug 07, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7hqg4k/peanut_allergy) has announced the addition of the "Peanut Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peanut Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peanut Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioTech Tools - DBV Technologies SA - HAL Allergy BV - Anergis SA - Immunomic Therapeutics, Inc. - Tunitas Therapeutics, Inc. - Perosphere Inc. - Sementis Ltd - Allergen Research Corporation Drug Profiles - DBV-712 - Allergen for Peanut Allergy - HALMPE-1 - ARA-LAMP-Vax - Recombinant Protein for Peanut Allergy - pnut-ASIT - DN-1017 - Vaccine for Peanut Allergy - Recombinant Vector Vaccine for Peanut Allergy - Vaccine for Peanut Allergy - PER-1080 For more information visit http://www.researchandmarkets.com/research/7h...ut_allergy
